ERBB2 and proximal spinal muscular atrophy: For instance, under the above considerations, one dose of Trastuzumab in the AC‐TH regimen for the treatment of HER2+ breast cancer costs around $900,144 while the antisense oligonucleotide drug Nusinersen for the treatment of spinal muscular atrophy is prized at $125,000 per injection.143 Therefore, for therapeutic DN to enter clinical trials, significant investments will be required due to the comparatively large costs of small‐scale GMP‐compliant oligonucleotide synthesis.